泌尿酸酶类型的等离子体激活剂和等离子体激活剂抑制剂-1复合物作为COVID-19的血清生物标志物
Tetiana Yatsenko1,2, Ricardo Rios3, Tatiane Nogueira3
1Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Frontiers in immunology
|February 5, 2024
概括
新的生物标志物,包括尿酶类型等离子体激活剂 (uPA) 和其与等离子体激活剂抑制剂-1 (PAI-1) 复合物的生物标志物,可以预测患者的严重COVID-19和急性呼吸困扰综合征 (ARDS) 发展.
科学领域:
- * 血液学 血液学
- * 免疫学 免疫学
- * 传染病 传染病
背景情况:
- * 冠状病毒疾病-2019 (COVID-19) 患者表现出血栓形成和急性呼吸困扰综合征 (ARDS) 风险的增加.
- *COVID-19中的血栓形成与高血原激活剂抑制剂-1 (PAI-1) 和纤维素分解受损有关.
- *在COVID-19中报告了尿素酶类型等离子体激活剂 (uPA),组织类型等离子体激活剂 (tPA) 和PAI-1的水平变化.
研究的目的:
- * 调查 uPA,tPA 和 PAI-1 的自由和复杂形式作为 COVID-19 严重程度和 ARDS 的生物标志物的预测价值.
- * 为了确定与严重的COVID-19结局相关的特定的uPA,tPA和PAI-1配置文件.
主要方法:
- * 对日本69名住院COVID-19患者和20名健康捐赠者的回顾性分析.
- *测量 uPA,tPA 和 PAI-1 的自由和复杂形式.
- *与临床严重性标志物,内皮功能障碍指标 (suPAR,sVCAM) 和炎症性细胞因子 (TNFα,IL1β,IL6,CRP) 的相关性分析.
主要成果:
- * 自由PAI-1抗原升高,低循环的uPA和uPA/PAI-1复合体与COVID-19严重程度和ARDS有关.
- *缺乏与内皮功能障碍标志物相关的PAI-1活性.
- * uPA/PAI-1复合体水平与炎症标志物和淋巴衰竭正相关.
结论:
- *免费的uPA和uPA/PAI-1复合体显示出潜在的新生物标志物,用于识别患有严重COVID-19和ARDS风险的患者.
- *这些生物标志物可能反映了COVID-19的复杂阶段,其特征是内皮功能障碍和炎症加剧.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
158
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
158
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
92
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
92